Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Vanishing bile duct syndrome arising in a patient with HIV infection sequentially treated with trimethoprim/sulfamethoxazole and dapsone.
Clin J Gastroenterol
April 2020
Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, USA.
Trimethoprim/sulfamethoxazole is well known to cause intra-hepatic cholestasis which in rare instances can be prolonged and lead to vanishing bile duct syndrome. The risk regarding the potential for cross-reactivity between structurally related molecules such as dapsone and trimethoprim/sulfamethoxazole in causing hepatotoxicity is scarce. Herein, we report a case of vanishing bile duct syndrome following dapsone use in a patient with HIV infection and a recent history of trimethoprim/sulfamethoxazole-induced cholestasis.
View Article and Find Full Text PDFUrosodeoxycholic Acid Therapy in a Child with Trimethoprim-Sulfamethoxazole-induced Vanishing Bile Duct Syndrome.
Pediatr Gastroenterol Hepatol Nutr
December 2013
Department of Pediatrics, Chungnam National University School of Medicine, Daejeon, Korea.
We present a case of a 7-year-old boy who had cholestasis after trimethoprim-sulfamethoxazole combination therapy. Liver biopsy was performed 36 days after the onset of jaundice because of no evidence of improving cholestasis. Liver histology revealed portal inflammation, bile plug, and biliary stasis around the central vein with the loss of the interlobular bile ducts.
View Article and Find Full Text PDFTrimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome.
Am J Gastroenterol
January 1997
Department of Medicine, University of California, San Diego, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!